Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

46.89 -0.14 (-0.30%)
Streaming Delayed Price Updated: 9:33 AM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Sanofi - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
36 37 Next >
News headline image
Alnylam Pharmaceuticals (ALNY): The RNAi Pioneer’s 2026 Breakout and the Battle for Cardiovascular Dominance
As of February 12, 2026, Alnylam Pharmaceuticals (NASDAQ: ALNY) has officially transcended its status as a high-potential biotech and entered the pantheon of global pharmaceutical powerhouses. Known as... 
Via Finterra
Topics Economy Intellectual Property
News headline image
FDA Stuns Moderna with Refusal to Review Flu Vaccine, Sending Shares Tumbling 3.5%
Shares of Moderna, Inc. (NASDAQ: MRNA) fell 3.5% on February 12, 2026, as investors continued to digest the fallout from a rare and unexpected regulatory setback. The U.S. Food and Drug Administration... 
Via MarketMinute
Topics Earnings
Disc Medicine, Sanofi, Eli Lilly Shares Slip On Reports Of FDA Increasing Review Time For Drugs Granted Priority Review Vouchers ↗
Via Stocktwits
News headline image
This Infrastructure Stock Surged Nearly 40% in One Year -- and One Fund Sold $11 Million in Shares ↗
Everus Construction Group delivers utility construction and specialty services across the Midwest and key urban markets. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Lilly Bolsters Immunology Arsenal with $1.2 Billion Acquisition of Ventyx Biosciences
In a strategic move to solidify its dominance in the burgeoning field of oral anti-inflammatories, Eli Lilly and Company (NYSE:LLY) announced on January 7, 2026, a definitive agreement to acquire... 
Via MarketMinute
News headline image
Eli Lilly Reinforces Immunology Dominance with $1.2 Billion Acquisition of Ventyx Biosciences
In a decisive move to solidify its leadership in the next generation of chronic inflammation and cardiometabolic treatments, Eli Lilly and Company (NYSE: LLY) announced the acquisition of Ventyx... 
Via MarketMinute
News headline image
Nasdaq, S&P 500 Futures Subdued Ahead Of PMI Data: Why INTC, TSLA, NFLX, VST, MOVE Are On Traders' Radar Today ↗
Retail sentiment on Stocktwits for SPY and QQQ remained ‘bearish’. 
Via Stocktwits
Topics ETFs Government Lawsuit
News headline image
AstraZeneca Signals End of an Era: Formal Move to NYSE Triggers Major Index Rebalancing
LONDON — January 20, 2026 — In a milestone moment for global capital markets, pharmaceutical giant AstraZeneca (NYSE: AZN) has officially filed its formal notice of voluntary withdrawal from the Nasdaq... 
Via MarketMinute
Topics Regulatory Compliance
News headline image
GSK Challenges Xolair Dominance with $2.2 Billion Acquisition of RAPT Therapeutics
In a bold strategic opening to the 2026 fiscal year, pharmaceutical giant GSK (NYSE:GSK) has announced a definitive agreement to acquire RAPT Therapeutics (Nasdaq:RAPT) for approximately $2.2 billion.... 
Via MarketMinute
Topics Intellectual Property
News headline image
The Battle for the White Coat: OpenAI and Anthropic Reveal Dueling Healthcare Strategies
In the opening weeks of 2026, the artificial intelligence industry has moved beyond general-purpose models to a high-stakes "verticalization" phase, with healthcare emerging as the primary... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
Anthropic’s New Specialized Healthcare Tiers: A New Era for AI-Driven Diagnostics and Medical Triage
On January 11, 2026, Anthropic, the AI safety and research company, officially unveiled its most significant industry-specific expansion to date: specialized healthcare and life sciences tiers for its... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
The mRNA 2.0 Inflection: A Deep Dive into Moderna (MRNA) as it Faces a Critical 2026
As of January 16, 2026, Moderna, Inc. (NASDAQ: MRNA) stands at a critical crossroads. Once the poster child for the biotechnology industry’s rapid response to a global pandemic, the Cambridge-based... 
Via Finterra
Topics Initial Public Offering Intellectual Property Lawsuit
News headline image
Eli Lilly’s $1.2 Billion Acquisition of Ventyx Biosciences: Bridging the Gap Between Weight Loss and Chronic Inflammation
In a bold move to solidify its dominance in the cardiometabolic market, Eli Lilly and Company (NYSE:LLY) announced on January 7, 2026, that it has entered into a definitive agreement to acquire Ventyx... 
Via MarketMinute
Topics Intellectual Property
News headline image
Why Did OCUL Stock Jump 13% In Pre-Market Today? ↗
French pharmaceutical giant Sanofi is preparing an offer to acquire the American biopharmaceutical firm, according to a report by French publication La Lettre. 
Via Stocktwits
News headline image
Anthropic Launches “Claude for Healthcare”: A Paradigm Shift in Medical AI Integration and HIPAA Security
On January 11, 2026, Anthropic officially unveiled Claude for Healthcare, a specialized suite of artificial intelligence tools designed to bridge the gap between frontier large language models and the... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
Cashing In at the Peak: Olema Pharmaceuticals Insiders Sell $8 Million in Stock After 300% Surge
Olema Pharmaceuticals (NASDAQ:OLMA) has become the latest focal point of biotech volatility and executive opportunism. Following a staggering 300% surge in its share price over the past year—fueled by... 
Via MarketMinute
News headline image
MoonLake Immunotherapeutics Surges as FDA "De-Risks" Sonelokimab, Reigniting Multi-Billion Dollar Takeover Speculation
MoonLake Immunotherapeutics (NASDAQ: MLTX) shares have experienced a dramatic resurgence this week, climbing over 40% following a pivotal regulatory update that has effectively cleared the path for its... 
Via MarketMinute
Topics Intellectual Property
News headline image
BioNTech Finalizes CureVac Acquisition: A Strategic Consolidation Met with Market Skepticism
In a move that signals the end of an era for independent mRNA pioneers, BioNTech SE (Nasdaq: BNTX) has officially completed its acquisition of longtime rival CureVac N.V. (Nasdaq: CVAC). The... 
Via MarketMinute
Topics Intellectual Property
News headline image
Moderna’s Second Act: A 2026 Deep Dive into the Future of mRNA Therapeutics
Today’s Date: January 9, 2026 Introduction As we enter the first weeks of 2026, Moderna, Inc. (NASDAQ: MRNA) finds itself at a defining crossroads. Once the poster child for the biotech boom of the... 
Via PredictStreet
Topics Initial Public Offering Intellectual Property
J&J Cuts Deal With Trump’s White House To Slash Drug Prices And Dodge Tariffs ↗
Via Stocktwits
Topics Government
News headline image
Trade War 2.0: Markets Braced as Trump’s 2026 Tariff ‘Salvos’ Reshape the Global Supply Chain
As of January 8, 2026, the global financial landscape is undergoing a seismic shift driven by President Trump’s latest round of "tariff salvos." These aggressive trade policies, which dominated the... 
Via MarketMinute
Topics Economy Government World Trade
News headline image
The 2026 Pharma M&A Outlook: Obesity, HIV, and the Biotech Renaissance
As the pharmaceutical industry rings in 2026, the landscape of healthcare investment has shifted from cautious recovery to a full-scale acquisition frenzy. Driven by a looming "super-cliff" of patent... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Moderna’s Second Act: Analyzing the 2026 Pipeline Pivot and Recent Stock Surge
Date: January 7, 2026 Introduction Moderna, Inc. (NASDAQ: MRNA), once the definitive poster child of the COVID-19 pandemic response, is currently undergoing one of the most significant pivots in the... 
Via PredictStreet
Topics Economy Initial Public Offering Intellectual Property
News headline image
The Great Unlocking: 2026 Opens with a Historic Surge in Large-Cap M&A Activity
The first week of 2026 has signaled a tectonic shift in the global financial landscape, as a wave of multi-billion dollar acquisitions has effectively ended the deal-making drought of the previous two... 
Via MarketMinute
Topics Artificial Intelligence Economy Energy
News headline image
Flu Season's Here—This Dividend-Payer Controls the Shot Market ↗
Via MarketBeat
Topics Artificial Intelligence Death
News headline image
BioMarin’s $4.8 Billion Amicus Acquisition: A Strategic Pivot to Rare Disease Dominance
In a move that has sent shockwaves through the biotechnology sector, BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced on December 19, 2025, that it has entered into a definitive agreement to... 
Via MarketMinute
Topics Economy Intellectual Property
News headline image
Pfizer Leads New Wave Of 2026 US Drug Price Hikes Despite Trump’s Drug Cost Crackdown: Report ↗
Drugmakers are outlining 2026 list price changes, with most adjustments typically announced in January. 
Via Stocktwits
Topics Economy Government
News headline image
Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal
The biopharmaceutical sector witnessed a dramatic surge in volatility today, December 29, 2025, as the industry careened toward the end of its strongest year in two decades. In a day defined by extreme... 
Via MarketMinute
Topics ETFs Intellectual Property
News headline image
The Dynavax Turnaround: From Clinical Setbacks to a $2.2 Billion Exit
As of December 26, 2025, the biotechnology landscape is processing one of the most significant mid-cap acquisitions of the year. Dynavax Technologies Corporation (NASDAQ: DVAX) has transitioned from a... 
Via PredictStreet
News headline image
The Great Vaccine Consolidation: Sanofi’s $2.2 Billion Strategic Bet on Dynavax Technologies
Dateline: December 25, 2025 Introduction In a move that has sent shockwaves through the biotechnology and pharmaceutical sectors on this Christmas Day, the global vaccine landscape has been... 
Via PredictStreet
Topics Economy Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
36 37 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.